1. Home
  2. SLXN
  3. SLXN News

Latest BIOMOTION SCIENCES (SLXN) News on February 23, 2025

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
SLXN

GlobeNewswire

24 days ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
SLXN

Business Wire

25 days ago

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
SLXN

GlobeNewswire

a month ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

SLXN

Business Wire

a month ago

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
SLXN

GlobeNewswire

a month ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
SLXN

GlobeNewswire

a month ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
SLXN

GlobeNewswire

a month ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Silexion Therapeutics, Evonik collaborate on siRNA formulation development
SLXN

TipRanks

2 months ago

Silexion Therapeutics, Evonik collaborate on siRNA formulation development

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
SLXN

Business Wire

2 months ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
SLXN

GlobeNewswire

2 months ago

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
SLXN

GlobeNewswire

2 months ago

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Silexion Therapeutics Announces 1-for-9 Reverse Share Split
SLXN

GlobeNewswire

3 months ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
SLXN

GlobeNewswire

3 months ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

SLXN

ACCESSWIRE

3 months ago

Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

SLXN

ACCESSWIRE

4 months ago

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
SLXN

Business Wire

5 months ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
SLXN

Business Wire

5 months ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
SLXN

Business Wire

5 months ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
SLXN

GlobeNewswire

6 months ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
SLXN

GlobeNewswire

6 months ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Share on Social Networks: